X-ray laser maps important drug target

Published: Friday, December 20, 2013 - 11:05 in Biology & Nature

Related images
(click to enlarge)

This illustration shows a man suffering from a migraine, overlain with a rendering of the human serotonin receptor bound to ergotamine, an anti-migraine drug. Also shown is a rendering of a neuron network. Scientists used SLAC's Linac Coherent Light Source X-ray laser to explore crystallized samples of the serotonin receptor, which is a type of G protein-coupled receptor. GPCRs regulate many important functions in human physiology; serotonin, for example, is a neurotransmitter that regulates mood, appetite and sleep.
Katya Kadyshevskaya/The Scripps Research Institute
A team led by Vadim Cherezov of The Scripps Research Institute views an X-ray diffraction pattern, produced when SLAC's Linac Coherent Light Source X-ray laser struck a crystallized sample of the human serotonin receptor. The team collected and analyzed more than 100,000 of these patterns to reproduce a 3-D structure of the receptor.
Fabricio Sousa/SLAC
This rendering shows the structure of the human serotonin receptor bound to ergotamine (green), an anti-migraine drug. The image also shows lipids (gray), palmitic acid (blue) and cholesterol (yellow).
The Scripps Research Institute

Researchers have used one of the brightest X-ray sources on the planet to map the 3-D structure of an important cellular gatekeeper known as a G protein-coupled receptor, or GPCR, in a more natural state than possible before. The new technique is a major advance in exploring GPCRs, a vast, hard-to-study family of proteins that plays a key role in human health and is targeted by an estimated 40 percent of modern medicines. The research, performed at the Linac Coherent Light Source (LCLS) X-ray laser at the Department of Energy's (DOE's) SLAC National Accelerator Laboratory, is also a leap forward for structural biology experiments at LCLS, which has opened up many new avenues for exploring the molecular world since its launch in 2009.

"For the first time we have a room-temperature, high-resolution structure of one of the most difficult to study but medically important families of membrane proteins," said Vadim Cherezov, a pioneer in GPCR research at The Scripps Research Institute who led the experiment. "And we have validated this new method so that it can be confidently used for solving new structures."

In the experiment, published Dec. 20 in Science, researchers examined the human serotonin receptor, which plays a role in learning, mood and sleep and is the target of drugs that combat obesity, depression and migraines. The scientists prepared crystallized samples of the receptor in a fatty gel that mimics its environment in the cell. With a newly designed injection system, they streamed the gel into the path of the LCLS X-ray pulses, which hit the crystals and produced patterns used to reconstruct a high-resolution, 3-D model of the receptor.

The method eliminates one of the biggest hurdles in the study of GPCRs: They are notoriously difficult to crystallize in the large sizes needed for conventional X-ray studies at synchrotrons. Because LCLS is millions of times brighter than the most powerful synchrotrons and produces ultrafast snapshots, it allows researchers to use tiny crystals and collect data in the instant before any damage sets in. As a bonus, the samples do not have to be frozen to protect them from X-ray damage, and can be examined in a more natural state.

"This is one of the niches that LCLS is perfect for," said SLAC Staff Scientist Sébastien Boutet, a co-author of the report. "With really challenging proteins like this you often need years to develop crystals that are large enough to study at synchrotron X-ray facilities."

Cherezov said that even after samples of a GPCR are crystallized and imaged, it can take several months to optimize the crystal size and collect enough synchrotron X-ray data to produce structural information. This study demonstrates that an LCLS experiment using smaller crystals can potentially condense that timeline to a matter of days.

Disorders linked to GPCRs include hypertension, asthma, schizophrenia and Parkinson's disease. Because of their vital role in regulating cells' signaling and response mechanisms and their importance to human health, advances in receptor-related research garnered the 2012 Nobel Prize in Chemistry.

So far, scientists have been able to map the structures of fewer than two dozen of the estimated 800 GPCRs in humans. Although the human serotonin structure had been determined earlier with conventional methods, that effort took much longer and showed the receptor in a less realistic environment. The more accurate the structure, the better scientists can use it to tailor effective drug treatments without side effects. Thus, this new technology could eventually lead to an efficient platform for designing drugs based on GPCR structures.

"I view these recent experiments as just the beginning," Cherezov said, "Now it is time to start making a serious impact on the field of structural biology of G protein-coupled receptors and other challenging membrane proteins and complexes. The pace of structural studies in this field is breathtaking, and there is still a lot unknown."

Source: DOE/SLAC National Accelerator Laboratory

Share

Other sources

2 more sources Click

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net